Skip to main content

Table 2 Demographics and clinical characteristics of patients associated with seizure recurrence, controlling for the competing risk of death (n = 95)

From: Mortality & recurrent seizure risk after new-onset seizure in HIV-positive Zambian adults

  Median time to seizure recurrence [IQR] P-valuea
Gender   0.960
 Male (n = 13) 3.1 [1.2–9.3]  
 Female (n = 10) 3.3 [0.5–14.6]  
Presenting seizure severity (n = 89)   < 0.01
 Status epilepticus (n = 17) 3.1 [1.2–9.3]  
 Not status epilepticus (n = 4) 1.5 [0.4–8.8]  
Evidence of seizure focality   0.339
 Yes (n = 14) 3.1 [1.2–9.3]  
 No (n = 9) 1.1 [0.5–8.8]  
WHO clinical stage   0.334
 I or II (n = 4) 6.4 [1.4–13.5]  
 III or IV (n = 19) 3.1 [0.9–9.3]  
cART use   0.105
 Yes (n = 8) 1.4 [0.3–6.3]  
 No, defaulted (n = 4) 2.8 [1.5–10.0]  
 No, never (n = 11) 8.6 [1.2–15.9]  
CSF collected for analysis   0.845
 Yes (n = 20) 3.5 [0.7–12.6]  
 No (n = 3) 2.6 [2.2–3.7]  
CNS opportunistic infection   0.788
 Yes (n = 5) 9.3 [8.7–15.9]  
 No (n = 18) 5.0 [0.9–8.6]  
Unknown seizure etiology   0.230
 Yes (n = 3) 1.2 [0.03–1.8]  
 No (n = 20) 3.8 [1.1–12.6]  
  1. Data is presented as median (IQR). aGray’s test of cumulative incidence functions. WHO, World Health Organization. cART combination antiretroviral therapy. CSF cerebrospinal fluid. CNS central nervous system